Long-Term Outcomes in Two-Year Follow-Up after Primary Treatment in Patients with a Prior Venous Thromboembolic Event : A Prospective, Observational, Real-Life Study
BACKGROUND: Patients with acute venous thromboembolism (VTE) need anticoagulation (AC) therapy for at least 3/6 months (primary treatment); after that period, they should receive a decision on the duration of therapy.
METHODS: This study examined the complications occurring during two years of follow-up (FU) in patients with a first VTE who were recruited in 20 clinical centers and had discontinued or prolonged AC. They were included in the START2-POST-VTE prospective observational study.
RESULTS: A total of 720 patients (53.5% males) who, after the completion of primary treatment, had received the decision to continue (n = 281, 39%; 76.1% with a DOAC) or discontinue (n = 439, 61%) AC were followed up for 2 years (total FU = 1318 years). The decision to prolong or suspend AC was made in similar proportions in patients with unprovoked or provoked index events. Courses of sulodexide treatment or Aspirin (100 mg daily) were prescribed to 20.3% and 4.5%, respectively, of the patients who discontinued AC. The bleeding rate was significantly higher in patients who extended AC (1.6% pt/y) than in those who stopped AC (0.1% pt/y; p = 0.001) and was higher in patients using standard-dose DOACs (3.1% pt/y) than in those using reduced-dose DOACs (0.4% pt/y). The recurrent VTE rates were similar between the two groups (2.2% pt/y during AC vs. 3% pt/y off AC).
CONCLUSION: Physicians' decisions about AC duration were independent of the unprovoked/provoked nature of the index event. The bleeding rate was higher in patients who continued AC using standard-dose DOACs. Surprisingly, the rate of thrombotic recurrence was not different between those who continued or discontinued AC. Randomized studies comparing different procedures to decide on the duration of AC after a first VTE are needed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 13(2024), 5 vom: 27. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Palareti, Gualtiero [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulant treatment |
|---|
| Anmerkungen: |
Date Revised 11.04.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm13051343 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370815203 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370815203 | ||
| 003 | DE-627 | ||
| 005 | 20240411232732.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240409s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm13051343 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM370815203 | ||
| 035 | |a (NLM)38592175 | ||
| 035 | |a (PII)1343 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Palareti, Gualtiero |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-Term Outcomes in Two-Year Follow-Up after Primary Treatment in Patients with a Prior Venous Thromboembolic Event |b A Prospective, Observational, Real-Life Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: Patients with acute venous thromboembolism (VTE) need anticoagulation (AC) therapy for at least 3/6 months (primary treatment); after that period, they should receive a decision on the duration of therapy | ||
| 520 | |a METHODS: This study examined the complications occurring during two years of follow-up (FU) in patients with a first VTE who were recruited in 20 clinical centers and had discontinued or prolonged AC. They were included in the START2-POST-VTE prospective observational study | ||
| 520 | |a RESULTS: A total of 720 patients (53.5% males) who, after the completion of primary treatment, had received the decision to continue (n = 281, 39%; 76.1% with a DOAC) or discontinue (n = 439, 61%) AC were followed up for 2 years (total FU = 1318 years). The decision to prolong or suspend AC was made in similar proportions in patients with unprovoked or provoked index events. Courses of sulodexide treatment or Aspirin (100 mg daily) were prescribed to 20.3% and 4.5%, respectively, of the patients who discontinued AC. The bleeding rate was significantly higher in patients who extended AC (1.6% pt/y) than in those who stopped AC (0.1% pt/y; p = 0.001) and was higher in patients using standard-dose DOACs (3.1% pt/y) than in those using reduced-dose DOACs (0.4% pt/y). The recurrent VTE rates were similar between the two groups (2.2% pt/y during AC vs. 3% pt/y off AC) | ||
| 520 | |a CONCLUSION: Physicians' decisions about AC duration were independent of the unprovoked/provoked nature of the index event. The bleeding rate was higher in patients who continued AC using standard-dose DOACs. Surprisingly, the rate of thrombotic recurrence was not different between those who continued or discontinued AC. Randomized studies comparing different procedures to decide on the duration of AC after a first VTE are needed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anticoagulant treatment | |
| 650 | 4 | |a bleeding | |
| 650 | 4 | |a long-term follow-up | |
| 650 | 4 | |a recurrence | |
| 650 | 4 | |a venous thromboembolism | |
| 700 | 1 | |a Antonucci, Emilia |e verfasserin |4 aut | |
| 700 | 1 | |a Bucherini, Eugenio |e verfasserin |4 aut | |
| 700 | 1 | |a Caronna, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Chistolini, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Di Giorgio, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Di Giulio, Rosella |e verfasserin |4 aut | |
| 700 | 1 | |a Falanga, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Fregoni, Vittorio |e verfasserin |4 aut | |
| 700 | 1 | |a Garzia, Mariagrazia |e verfasserin |4 aut | |
| 700 | 1 | |a Mastroiacovo, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Marzolo, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Pancani, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Pastori, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Podda, Gian Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Rigoni, Anna Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Ria, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Sivera, Piera |e verfasserin |4 aut | |
| 700 | 1 | |a Testa, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Visonà, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Parisi, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Poli, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a On Behalf Of The Start Post Vte Investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 13(2024), 5 vom: 27. Feb. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:5 |g day:27 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm13051343 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 5 |b 27 |c 02 | ||